Safety and Efficacy of Biosimilar Infliximab Treatment in IBD Patients Presented at DDW 2015

Safety and Efficacy of Biosimilar Infliximab Treatment in IBD Patients Presented at DDW 2015
Celltrion Healthcare and Jørgen Jahnsen, Professor of Gastroenterology at the University of Oslo in Norway recently presented at the Digestive Diseases Week (DDW) 2015 in Washington D.C. results from a study that examined the effects of biosimilar infliximab in 78 patients with inflammatory bowel disease (IBD). The results showed that the treatment is as effective and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *